TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
MADISON, Wis., Sept. 29, 2017 -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the “company”), today announced that president and CEO Jim Caruso will present and meet with investors at The MicroCap Conference on Thursday, October 5th at 12:30 PM ET at The Essex House in New York City.
The live presentation will be webcast at http://microcapconf.com/conferences/new-york-2-2017, and archived on the company’s website following the conference.
About Cellectar Biosciences, Inc.
Cellectar Biosciences (Nasdaq:CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers, even sites of metastases. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 has been designated as an orphan drug by the US FDA and is currently being evaluated in a Phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a Phase 2 clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing proprietary PDCs for targeted delivery of chemotherapeutics and has several preclinical stage product candidates, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit www.cellectar.com.
Contact:
Jules Abraham
JQA Partners, Inc.
917-885-7378
[email protected]
